Astute Extends Series B Funding to $39.5M
San Diego’s Astute Medical, which raised $26.5 million in a Series B venture round last May, says it has extended the round and raised an additional $13 million to develop new diagnostic tests for acute conditions that require rapid diagnosis. Investors include Domain Associates, Delphi Ventures, De Novo Ventures and Johnson & Johnson Development Corporation. The company raised $6.2 million in its Series A round of venture funding in 2008. The startup, founded in 2007 by CEO Christopher Hibberd and chief scientific officer Paul McPherson Ph.D., has been working to identify protein biomarkers that could be used to help diagnose such critical issues as kidney injury, acute coronary syndromes, cerebrovascular injury, abominal pain, and sepsis.